Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-Acetylcysteine in NAFLD
NCT05576428Unknown
- Sponsor
- Dow University of Health Sciences
- Start
- Nov 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of acetylcysteine in non-alcoholic fatty liver disease (NAFLD), sponsored by Dow University of Health Sciences. Primary endpoints: Alanine transaminase at 12 weeks and Aspartate aminotransferase at 12 weeks. Status: unknown.
02
Drugs
acetylcysteine
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05576428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05576428.